Taken together, our data showed that small molecule inhibition of PRL-3 can block T-ALL growth and migration in vitro, likely due to Src inhibition, and suggest that PRL-3 might be a useful target to control T-ALL progression. Here, PTP4A3 is linked to acute lymphoblastic leukemia.